FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]
연구 도서관으로 돌아가기

Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]

November 20, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]

A new clinical trial set to begin in 2027 aims to explore whether semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist commonly used for weight management, can also help individuals struggling with alcohol use disorder (AUD). The study, registered on ClinicalTrials.gov under identifier NCT07949474, is being conducted by the University of Minnesota and will involve 128 adults who are both obese and have AUD.

The trial's primary objective is to determine if semaglutide can effectively reduce alcohol consumption and improve overall health outcomes in this population. This research could open up new avenues for treating dual conditions that often co-occur, such as obesity and AUD, which currently lack targeted therapies.

Background

Alcohol use disorder is a significant public health concern, affecting millions of people worldwide. It can lead to numerous physical and mental health issues, including liver disease, heart problems, depression, and anxiety disorders. Additionally, many individuals with AUD also struggle with obesity, further complicating their treatment options. Current treatments for AUD are limited, and there's an urgent need for more effective medications that address both alcohol dependence and associated weight gain.

Semaglutide has already shown promise in managing type 2 diabetes and obesity through its mechanism of action on the GLP-1 receptor pathway. By mimicking natural peptides involved in appetite regulation and glucose metabolism, semaglutide can help reduce food intake and promote satiety. The potential for this medication to also impact alcohol consumption is intriguing, especially given the overlap between pathways involved in hunger and cravings.

Key Details

The upcoming trial will be a randomized, double-blind, placebo-controlled study lasting 45 weeks. Participants will receive either semaglutide or a placebo, with clinical assessments conducted regularly throughout the duration of the trial to monitor changes in alcohol use patterns and body weight. The primary outcome measures include reductions in alcohol consumption and improvements in overall health metrics.

Researchers hope that by targeting both obesity and AUD simultaneously, they can achieve better long-term outcomes for patients struggling with these conditions. Previous studies have suggested that addressing one condition may positively influence the other, making semaglutide a promising candidate for integrated treatment approaches.

Key Takeaways

  • Semaglutide Trial Launch: A new clinical trial will investigate whether semaglutide can help individuals with both AUD and obesity.
  • Dual Condition Management: The study aims to address two common health issues simultaneously, potentially offering more comprehensive care options.
  • GLP-1 Receptor Agonist Mechanism: Semaglutide's effects on GLP-1 receptors may extend beyond weight management to impact alcohol use behavior.
  • Clinical Trial Design: The trial will be randomized, double-blind, and placebo-controlled, ensuring robust data collection.

What This Means

For the peptide research community, this study represents a significant step forward in exploring novel therapeutic applications for existing peptides. If successful, it could pave the way for broader acceptance of GLP-1 receptor agonists like semaglutide as part of integrated treatment plans for complex health conditions involving both metabolic and behavioral components.

Moreover, this trial underscores the growing recognition of the interconnectedness between various health issues and the importance of holistic approaches in medical research. As more studies like these emerge, we can expect to see a richer understanding of how peptides can be leveraged across different therapeutic areas, ultimately benefiting patients with multifaceted health challenges.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.